This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.

Released: July 12, 2026·Last reviewed: October 15, 2026·Methodology v4.1

Researched By

Medical Researcher · Western University of Health Sciences

Medically Reviewed By

Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: October 15, 2026 · This page is informational and does not constitute medical advice.

This page is maintained. Prices are re-read at source and dated; evidence is checked against the published trial. Newest across the site: news · research · corrections.

Ipamorelin: evidence, legality and safety

Quick answer

FDA status, read October 15, 2026Ipamorelin: Withdrawn for 503A; still Category 2 under 503B. FDA’s Category 2 page lists ipamorelin acetate as withdrawn for 503A but keeps it in Category 2 under the 503B interim policy. It was not on the July 2026 agenda. What the July vote did and did not change → Sources: FDA Category 2 page · 503A category lists (May 14, 2026).

Ipamorelin is a selective growth-hormone secretagogue (a ghrelin-receptor agonist) marketed for GH release with fewer off-target effects than older secretagogues. It is NOT an FDA-approved finished consumer drug, and human outcome evidence is limited.

Regulatory statusNot FDA-approved as a finished consumer drug.

What does the evidence actually show?

What human clinical evidence exists?

Early-phase pharmacology exists; long-term efficacy and safety outcome data for marketed uses are limited.

What do the animal and laboratory studies show?

Preclinical data show selective GH release. We keep animal and laboratory findings clearly separated from human evidence, because preclinical results routinely fail to translate to people.

What are the known and potential risks?

Unregulated sourcing, unknown long-term safety, and the general risks of manipulating the GH axis.

No consumer dosing for research compoundsThis page does not provide dosing instructions for unapproved compounds, and we do not link to research-chemical sellers. If you are considering peptide therapy, do it through a licensed clinician who can weigh your individual risks.

Is it legal, and where does it come from?

The lawful pathway for any prescription peptide is a licensed clinician and a licensed pharmacy. Products labeled "for research use only" are not lawfully sold for human consumption. See how to verify a peptide provider and research peptides versus prescription therapy.

Is it banned in sport?

Prohibited as a GH secretagogue; verify the current WADA list.

Frequently asked questions

Is Ipamorelin FDA-approved?

Not FDA-approved as a finished consumer drug.

Is there human evidence for Ipamorelin?

Early-phase pharmacology exists; long-term efficacy and safety outcome data for marketed uses are limited.

Is Ipamorelin legal to buy?

Many peptides in this category are sold as 'research chemicals,' which is not a lawful pathway for human use. Legitimacy depends on approval status and whether a licensed clinician and pharmacy are involved. We do not link to research-chemical sellers.

Is Ipamorelin banned in sport?

Prohibited as a GH secretagogue; verify the current WADA list.

Sources

U.S. Food and Drug Administration — enforcement actions and warnings on unapproved peptide products.
World Anti-Doping Agency (WADA) Prohibited List — current edition.
Peer-reviewed preclinical and (where available) clinical literature, graded for evidence quality.

Spotted an error? Submit a correction.

How the dates on this page work. Manufacturer self-pay prices were re-read on 15 October 2026: NovoCare’s Wegovy page and Lilly’s Zepbound savings page. Foundayo prices are carried from LillyDirect pages archived 25 September 2026, because lilly.com blocked automated reads. Figures captured from telehealth provider websites carry the date we read that provider’s page, which may be earlier; where it is, the row or a dated notice says so. We do not restamp a figure we have not re-read.